Evidence map›Paper›PMID 33291316›Full record

ArticleInternational journal of molecular sciences2020

Downregulation of miR-506-3p Facilitates EGFR-TKI Resistance through Induction of Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines.

Inamul Haque, Hameem I Kawsar, Hannah Motes, Mukut Sharma, Snigdha Banerjee, Sushanta K Banerjee, Andrew K Godwin, Chao H Huang

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 33 citations in OpenAlex.

  1. Inhibition of GPR4 Ameliorates Neuropathic Pain and Neuronal Ferroptosis via Regulation of Spinal RhoA/YAP Signaling in Rats.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Phosphorylation of AGO2 by TBK1 Promotes the Formation of Oncogenic miRISC in NSCLC.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  10. Review
  11. Non-Coding RNAs as Key Regulators in Lung Cancer.International journal of molecular sciences · 2023
    Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Functions of non-coding RNAs in regulating cancer drug targets.Acta biochimica et biophysica Sinica · 2022
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Inamul HaqueCancer Research Unit, Veterans Affairs Medical Center, Kansas City, MO 64128, USA.
Hameem I KawsarDivision of Medical Oncology, University of Kansas Medical Center, Kansas City, KS 66160, USA.ORCID 0000-0002-3639-5927
Hannah MotesCancer Research Unit, Veterans Affairs Medical Center, Kansas City, MO 64128, USA.
Mukut SharmaResearch Service, Veterans Affairs Medical Center, Kansas City, MO 64128, USA.
Snigdha BanerjeeCancer Research Unit, Veterans Affairs Medical Center, Kansas City, MO 64128, USA.
Sushanta K BanerjeeCancer Research Unit, Veterans Affairs Medical Center, Kansas City, MO 64128, USA.
Andrew K GodwinDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA.ORCID 0000-0002-3987-9580
Chao H HuangCancer Research Unit, Veterans Affairs Medical Center, Kansas City, MO 64128, USA.
Veterans Health Administration · USUniversity of Kansas Medical Center · US

Funding

Using Integrated Omics to Identify Dysfunctional Genetic Mechanisms Influencing Schizophrenia and Sleep DisturbancesP20GM130423 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Kalyani Pyaram, Steven Allan Soper · 2019 to 2026
$21.5M
American Cancer Society IRGBLRD VA I01 BX001002BLRD VA I01 BX001989BLRD VA I01 BX004497BLRD VA IK6 BX005769NIGMS NIH HHS P20 GM130423
6 · The paper itself

Abstract

Non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation eventually develop resistance to EGFR-targeted tyrosine kinase inhibitors (TKIs). Treatment resistance remains the primary obstacle to the successful treatment of NSCLC. Although drug resistance mechanisms have been studied extensively in NSCLC, the regulation of these mechanisms has not been completely understood. Recently, increasing numbers of microRNAs (miRNAs) are implicated in EGFR-TKI resistance, indicating that miRNAs may serve as novel targets and may hold promise as predictive biomarkers for anti-EGFR therapy. MicroRNA-506 (miR-506) has been identified as a tumor suppressor in many cancers, including lung cancer; however, the role of miR-506 in lung cancer chemoresistance has not yet been addressed. Here we report that miR-506-3p expression was markedly reduced in erlotinib-resistant (ER) cells. We identified Sonic Hedgehog (SHH) as a novel target of miR-506-3p, aberrantly activated in ER cells. The ectopic overexpression of miR-506-3p in ER cells downregulates SHH signaling, increases E-cadherin expression, and inhibits the expression of vimentin, thus counteracting the epithelial-mesenchymal transition (EMT)-mediated chemoresistance. Our results advanced our understanding of the molecular mechanisms underlying EGFR-TKI resistance and indicated that the miR-506/SHH axis might represent a novel therapeutic target for future EGFR mutated lung cancer treatment.

Indexed as

Drug Resistance, NeoplasmAntineoplastic AgentsCadherinsCarcinoma, Non-Small-Cell LungCell Line, TumorDown-RegulationErbB ReceptorsErlotinib HydrochlorideGene Expression Regulation, NeoplasticHedgehog ProteinsHumansLung NeoplasmsMicroRNAsProtein Kinase InhibitorsSignal TransductionAntineoplastic AgentsCadherinsErbB ReceptorsErlotinib HydrochlorideHedgehog ProteinsMicroRNAsMIRN506 microRNA, humanProtein Kinase InhibitorsSHH protein, humanEGFRmiR-506-3pnon-small-cell lung cancer (NSCLC)resistanceSonic Hedgehogtyrosine kinase inhibitor (TKI)

Identifiers

PMID33291316
PMCPMC7729622
OpenAlexW3111809273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.